Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Another Alzheimer's Disease Failure

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Be it efficacy or safety, Eli Lilly (NYSE: LLY  ) just can't win with its Alzheimer's disease program .

The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor. Eli Lilly stopped a phase 2 trial after some patients had abnormal liver biochemical tests. Companies routinely run liver tests on clinical trial patients because it's one of the most common safety issues that affect drugs. The liver's job, after all, is to filter toxins out of the blood stream.

Lilly told the Wall Street Journal that it doesn't believe the liver toxicity has to do with the mechanism of inhibiting BACE and is most likely an off-target effect. That's good news for Merck (NYSE: MRK  ) , which has its own BACE inhibitor, MK-8931. The company has already moved the drug into a phase 2/3 trial. If there is an issue, it'll likely be discovered in the phase 2 portion that's enrolling 200 patients.

Assuming there's no class effect, LY2886721's demise is good news for Merck as long as there's no class effect. Merck had a lead, but it wasn't enough to make a difference commercially. It's also good news for AstraZeneca (NYSE: AZN  ) , which has a BACE inhibitor, AZD3293, licensed from Astex Pharmaceuticals (UNKNOWN: ASTX.DL  ) , that entered a phase 1 trial last December .

Assuming, of course, that the drug works. It's not clear yet if targeting BACE will slow or reduce the symptoms of Alzheimer's disease. In a phase 1 trial, MK-8931 reduced the amount of beta-amyloid in cerebral spinal fluid by more than 90%, but it isn't known whether that will reduce the amyloid plaques seen in Alzheimer's patients' brains, and, even if it does reduce the plaque formation, whether that will have a clinical effect.

Failures abound
Rather than because of safety, most Alzheimer's disease drug failures -- and there have been a lot of them -- have fallen short because of lack of efficacy.

Eli Lilly's solanezumab failed a couple of trials last year. The company is retesting the drug in a different population. I wouldn't hold my breath.

And there was Pfizer, Johnson & Johnson, and Elan (UNKNOWN: ELN.DL2  ) that proved that having more companies developing a drug doesn't make it any more likely to succeed. The company's Alzheimer's disease drug bapineuzumab failed four different clinical trials last year.

And I could go on. But let's not. It's depressing.

Give up?
I doubt companies are going to throw in the towel. As hard as it's been to develop a successful Alzheimer's drug, the rewards are great enough to justify the failures. From a company's perspective, even drugs that have a low likelihood of succeeding, like solanezumab, are probably worth rolling the dice on.

Investors, on the other hand, would be best off not assigning any value to Alzheimer's disease pipeline drugs. If a company does finally figure out the magical formula, investors can benefit from the unexpected pop.

With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 16, 2013, at 10:40 AM, Profbam wrote:

    Two issues with these drugs. First, b-secretase has an I'm portent normal function in the brain. And it is still not clear whether b-amyloid-42 is cause or side-product in Alzheimer's. second, when someone is diagnosed with Alzheimer's, most of the damage is already done--billions of neurons are gone and not coming back. If diagnosed while symptoms are mild and the process stopped, that would be good. Namenda has that mechanism and minimal toxicity. We need more and we need very early detection, think rapid accurate inexpensive test for mass screening.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2490824, ~/Articles/ArticleHandler.aspx, 9/28/2016 3:12:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:01 PM
LLY $80.88 Up +1.36 +1.71%
Eli Lilly and Co. CAPS Rating: ***
ASTX.DL $0.00 Down +0.00 +0.00%
Astex Pharmaceutic… CAPS Rating: ***
AZN $33.61 Up +0.06 +0.18%
AstraZeneca CAPS Rating: ****
ELN.DL2 $0.00 Down +0.00 +0.00%
Elan CAPS Rating: ***
JNJ $119.22 Up +1.44 +1.22%
Johnson and Johnso… CAPS Rating: *****
MRK $62.57 Up +0.42 +0.68%
Merck and Co. CAPS Rating: ****
PFE $33.83 Up +0.19 +0.56%
Pfizer CAPS Rating: ****